Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease

por Insel, Philip S, Mattsson, Niklas, Mackin, R Scott, Kornak, John, Nosheny, Rachel, Tosun-Turgut, Duygu, Donohue, Michael C, Aisen, Paul S, Weiner, Michael W
Publicado 2015

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease

por Caspell-Garcia, Chelsea, Simuni, Tanya, Tosun-Turgut, Duygu, Wu, I-Wei, Zhang, Yu, Nalls, Mike, Singleton, Andrew, Shaw, Leslie A., Kang, Ju-Hee, Trojanowski, John Q., Siderowf, Andrew, Coffey, Christopher, Lasch, Shirley, Aarsland, Dag, Burn, David, Chahine, Lana M., Espay, Alberto J., Foster, Eric D., Hawkins, Keith A., Litvan, Irene, Richard, Irene, Weintraub, Daniel
Publicado 2017

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

por Marek, Kenneth, Chowdhury, Sohini, Siderowf, Andrew, Lasch, Shirley, Coffey, Christopher S., Caspell‐Garcia, Chelsea, Simuni, Tanya, Jennings, Danna, Tanner, Caroline M., Trojanowski, John Q., Shaw, Leslie M., Seibyl, John, Schuff, Norbert, Singleton, Andrew, Kieburtz, Karl, Toga, Arthur W., Mollenhauer, Brit, Galasko, Doug, Chahine, Lana M., Weintraub, Daniel, Foroud, Tatiana, Tosun‐Turgut, Duygu, Poston, Kathleen, Arnedo, Vanessa, Frasier, Mark, Sherer, Todd
Publicado 2018